- Home
- ARMP vs GECC Comparison
ARMP vs GECC Comparison
Compare ARMP & GECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARMP | GECC |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.7M | 107.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ARMP | GECC |
|---|---|---|
| Price | $5.76 | $6.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $9.00 | ★ $10.75 |
| AVG Volume (30 Days) | 69.4K | ★ 91.2K |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 19.82% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $5,054,000.00 | ★ $46,553,000.00 |
| Revenue This Year | $4.48 | $32.16 |
| Revenue Next Year | N/A | $3.26 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 17.68 |
| 52 Week Low | $0.90 | $7.18 |
| 52 Week High | $16.34 | $11.46 |
Technical Indicators
Market Signals| Indicator | ARMP | GECC |
|---|---|---|
| Relative Strength Index (RSI) | 46.09 | 31.24 |
| Support Level | $5.67 | $7.57 |
| Resistance Level | $6.39 | $7.95 |
| Average True Range (ATR) | 0.58 | 0.23 |
| MACD | -0.13 | -0.05 |
| Stochastic Oscillator | 18.49 | 8.30 |
Price Performance
Historical ComparisonAbout ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.